A Phase I, Randomized, Double blinded, Adaptive, Single and Multiple Ascending Dose Study of the Safety and Tolerability of NPI 001 Solution in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2018
At a glance
- Drugs N-acetylcysteine-amide (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions
- Sponsors Nacuity Pharmaceuticals
- 09 Apr 2018 Status changed from recruiting to completed.
- 12 Sep 2017 Status changed from not yet recruiting to recruiting.
- 24 Jun 2017 New trial record